Biomarkers Overview
JH · Effective Oct 1, 2015
19 active Medicare policies list 0333U, and 4 commercial payer policies list it. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
JH · Effective Oct 1, 2015
JL · Effective Oct 1, 2015
J9 · Effective Jul 17, 2023
JH · Effective Jul 17, 2023
JL · Effective Jul 17, 2023
J15 · Effective Oct 1, 2015
JE · Effective Oct 1, 2015
JF · Effective Oct 1, 2015
JJ · Effective Oct 1, 2015
4 policies from 2 payers
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
| Policy | Effective | Status of 0333U |
|---|---|---|
| Genetic Liquid Biopsy in the Management of Cancer and Cancer Surveillance The retained document does not establish a state, line of business, or indexed market. Applicability is unknown; confirm the member's plan with the payer. | Aug 22, 2026 | Covered |
| Genetic Liquid Biopsy in the Management of Cancer and Cancer Surveillance [for Indiana Medicaid] The retained document does not establish a state, line of business, or indexed market. Applicability is unknown; confirm the member's plan with the payer. | Jun 14, 2026 | Covered |
| Somatic Tumor Testing The retained document does not establish a state, line of business, or indexed market. Applicability is unknown; confirm the member's plan with the payer. |
JM · Effective Oct 1, 2015
J5 · Effective Feb 16, 2017
J8 · Effective Feb 16, 2017
J9 · Effective Oct 1, 2015
National · Effective Jul 1, 2026
National · Effective Jul 1, 2026
National · Effective Jul 1, 2026
J5 · Effective Jul 1, 2026
JL · Effective Jul 1, 2026
J9 · Effective Jul 1, 2026
| Nov 15, 2025 |
| Covered |
| Policy | Effective | Status of 0333U |
|---|---|---|
| Circulating Tumor DNA and Circulating Tumor Cells for Management (Liquid Biopsy) of Solid Tumor Cancers | Oct 1, 2026 | Covered |